<!DOCTYPE html><html lang="en" class="page"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1"><link rel="shortcut icon" href="favicon.ico" type="image/x-icon"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta name="theme-color" content="#111111"><title>Capnia CoSense Studies</title><link rel="preload" href="fonts/WorkSansRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansMedium.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansBold.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowBold.woff2" as="font" type="font/woff2" crossorigin><link rel="stylesheet" href="css/vendor.css"><link rel="stylesheet" href="css/main.css"><script defer="defer" src="js/main.js"></script></head><body class="page__body"><a class="skiplink" href="#main-cosense-studies">Go to main content</a><div class="site-container"><header class="header header--products"><div class="header__container container-additional"><a class="header__logo" href="index.html"><img src="./img/logo.svg" class="header__logo-image" width="176" height="40" alt="Capnia logo"></a><nav class="header__nav" aria-label="Main navigation" data-menu><ul class="header__nav-list"><li class="header__nav-item"><a class="header__nav-link header__nav-link--home" href="index.html">Home</a></li><li class="header__nav-item"><a class="header__nav-link" href="products.html"><i>CoSense <span>®</span> </i>Product</a></li><li class="header__nav-item header__nav-item--dropdown"><button class="header__nav-link js-btn-dropdown" type="button" aria-label="Open submenu navigation">Clinical Resources</button><div class="dropdown"><div class="dropdown__wrapper"><ul class="dropdown__list"><li class="dropdown__item"><a class="dropdown__link dropdown__link--studies" href="cosense-studies.html"><span class="dropdown__link-text"><i>CoSense <span>®</span> </i></span>Studies</a></li><li class="dropdown__item"><a class="dropdown__link" href="bibliography.html">Bibliography</a></li><li class="dropdown__item"><a class="dropdown__link" href="guidelines.html">Guidelines</a></li></ul></div></div></li><li class="header__nav-item"><a class="header__nav-link" href="about.html">About Us</a></li><li class="header__nav-item"><a class="header__nav-link header__nav-link--contact" href="#">Contact Us</a></li></ul></nav><button class="header__burger" aria-label="Open menu" aria-expanded="false" data-burger><span class="header__burger-line"></span></button></div></header><main class="page__main" id="main-cosense-studies"><section class="clinical-resources"><div class="container"><div class="clinical-resources__wrapper"><h1 class="clinical-resources__title title-huge">Clinical Resources</h1><ul class="clinical-resources__list"><li class="clinical-resources__item"><a class="clinical-resources__link clinical-resources__link--active" href="cosense-studies.html"><i>CoSense</i> Studies</a></li><li class="clinical-resources__item"><a class="clinical-resources__link" href="bibliography.html">Bibliography</a></li><li class="clinical-resources__item"><a class="clinical-resources__link" href="guidelines.html">Guidelines</a></li></ul><div class="clinical-resources__text text-huge"><p>Review nearly 10 years of clinical research using the <i>CoSense <span>®</span> </i>ETCOc monitor.</p></div></div></div></section><section id="clinical-resources-info-cosense-studies" class="clinical-resources-info clinical-resources-info--cosense-studies"><div class="clinical-resources-info__container clinical-resources-info__container--cosense-studies container"><div class="clinical-resources-info__wrapper clinical-resources-info__wrapper--cosense-studies"><a class="clinical-resources-info__download text-medium" href="capnia-clinical-studies-2024-final.pdf" title="click to download pdf file" download><img class="clinical-resources-info__download-img" src="./img/clinical-resources-download-img.png" width="160" height="207" alt="" aria-hidden="true" loading="lazy"> Download the PDF </a><a class="clinical-resources-info__to-top clinical-resources-info__to-top--cosense-studies" href="#clinical-resources-info-cosense-studies">top</a><div class="clinical-resources-info__inner clinical-resources-info__inner--cosense-studies"><div class="clinical-resources-info__content"><h2 class="clinical-resources-info__title clinical-resources-info__title--cosense-studies"><i>CoSense</i> Studies Table</h2><search class="clinical-resources-info__search"><form class="clinical-resources-info__form" action="#" id="clinical-resources-info-form" method="POST"><input class="clinical-resources-info__input" type="search" id="clinical-resources-info-seacrh" name="searchQuery" placeholder="Search" title="Enter your search query" autocomplete="off"> <button class="clinical-resources-info__button" type="submit" form="clinical-resources-info-form"></button></form></search></div><table class="clinical-resources-info__table"><caption class="visually-hidden">Clinical Resources on End-Tidal Carbon Monoxide (ETCOc) in Neonatal Hemolysis</caption><thead class="clinical-resources-info__table-thead"><tr><th>Citation</th><th>Sample size & Inclusion criteria</th><th>Country of origin</th><th>Conclusions</th></tr></thead><tbody class="clinical-resources-info__table-tbody"><tr><td data-title="Citation"><span>2023</span> <span>Christensen RD, Bahr TM, Pakeeto S, Supapannachart S, Zhang, HY.</span> <span><i>Current Ped. Reviews</i> 2023, 19, 376-387</span></td><td data-title="Sample size & Inclusion criteria"></td><td data-title="Country of origin">USA, Thailand, China</td><td data-title="Conclusions"><ul><li>Established normal reference intervals for ETCOc in various perinatal populations can be used to (1) identify patients with hemolytic disorders from any cause, (2) characterize the severity of hemolysis in each patient, and (3) predict and prevent co-morbidities, and thereby improving outcomes.</li><li>Reports and theories support the use of ETCOc methodology to diagnose and quantify hemolytic disorder in term and premature neonates, anemic pregnant women, and fetuses in utero.</li></ul></td></tr><tr><td data-title="Citation"><span>2023</span> <span>Yang G, Deng L, Zhang K, Yuan Y, Zhang H.</span> <span>Pediatric Academic Societies (PAS) Presentation, April 2023</span></td><td data-title="Sample size & Inclusion criteria">n=2500 &lt; 35 wks, TB &gt;40th percentile</td><td data-title="Country of origin">China</td><td data-title="Conclusions"><ul><li>The use of ETCOc with TCB can decrease the rate of first phototherapy within 7 days of life (DOL) by 23% and it is associated with early identification of infants who needed phototherapy.</li><li>The intervention group received risk assessment based on ETCOc &lt; 1.5 ppm indicates low risk, > 1.5 ppm indicates increased risk for hemolysis. The intervention group started phototherapy earlier with higher ETCOc level but similar TCB/TSB.</li></ul></td></tr><tr><td data-title="Citation"><span>2023</span> <span>Du L.</span> <span>Pediatric Academic Societies (PAS) Presentation, April 2023</span></td><td data-title="Sample size & Inclusion criteria">Review of studies</td><td data-title="Country of origin"></td><td data-title="Conclusions"><ul><li>The predominant cause of elevated TSB is an increase in bilirubin production primarily due to ongoing hemolysis.</li><li>The diagnosis of ABO hemolytic disease of the newborn (HDN) and optimal management can be improved by ETCOc technology.</li><li>ETCOc, in combination with TSB/TcB, can be used to identify and predict hemolytic hyperbilirubinemia requiring phototherapy or readmission in the early postnatal period (late-first week of life).</li></ul></td></tr><tr id="test-222"><td data-title="Citation"><span>2023</span> <span>Christensen RD, Bahr TM, Wong RJ, Vreman HJ, Bhutani VK, Stevenson DK.</span> <span><i>J Perinatol.</i> 2023 Jul 19.</span></td><td data-title="Sample size & Inclusion criteria">Clinically available tests for hemolysis</td><td data-title="Country of origin">USA</td><td data-title="Conclusions"><ul><li>ETCOc measurement is the "Gold Standard" to diagnose hemolysis in a neonate and infant and best fulfills the AAP 2022 recommendation to “identify neonates with hemolysis from any cause.”</li><li>ETCOc is reproducible, have few false positives and false negatives, and is as sensitive and specific as is carboxyhemoglobin quantification.</li><li>The test is easy to perform, rapid (one to two minutes), and noninvasive.</li><li>Making a confident diagnosis of hemolysis can identify neonates that need: (1) vigilant monitoring of bilirubin and hemoglobin levels; (2) phototherapy; (3) post-phototherapy bilirubin monitoring; and (4) outpatient follow-up and neurodevelopmental assessment.</li></ul></td></tr><tr id="test-226"><td data-title="Citation"><span>2022</span> <span>Bao Y, Zhu J, Ma L, Zhang H, Sun L, Xu C, et al.</span> <span>J Pediatr.2022;250:16–21.e3.</span></td><td data-title="Sample size & Inclusion criteria">L, Xu C, et al. J Pediatr.2022;250:16–21.e3. 455 35-42 wks, 2500g, 12-120 HOL</td><td data-title="Country of origin">China</td><td data-title="Conclusions"><ul><li>Establish a reference nomogram for end-tidal CO corrected for ambient CO (ETCOc) levels in term and late-preterm newborns and its efficacy to identify hemolytic HB.</li><li>For predicting HB requiring predischarge phototherapy in the early postnatal period, the combination of ETCOc ≥75th percentile and TSB/TcB ≥75th percentile had the best sensitivity (92.1%).</li><li>The combination of ETCOc ≥95th percentile and TSB/TcB ≥75th percentile yielded the best specificity (97.8%).</li><li>For predicting readmission for HB, ETCOc > 1.7 ppm in the late postnatal period had the highest AUC (0.82), the combination of ETCOc ≥95th percentile and TSB/TcB ≥75th percentile had a specificity of 98.4%, 90.5% readmitted infants had predischarge ETCOc ≥75th percentile.</li></ul></td></tr><tr id="test-172"><td data-title="Citation"><span>2023</span> <span>Yang G, Deng L, Zhang K, Yuan Y, Zhang H.</span> <span>Pediatric Academic Societies (PAS) Presentation, April 2023</span></td><td data-title="Sample size & Inclusion criteria">n=2500 &lt; 35 wks, TB &gt;40th percentile</td><td data-title="Country of origin">China</td><td data-title="Conclusions"><ul><li>Established normal reference intervals for ETCOc in various perinatal populations can be used to (1) identify patients with hemolytic disorders from any cause, (2) characterize the severity of hemolysis in each patient, and (3) predict and prevent co-morbidities, and thereby improving outcomes.</li><li>Reports and theories support the use of ETCOc methodology to diagnose and quantify hemolytic disorder in term and premature neonates, anemic pregnant women, and fetuses in utero.</li></ul></td></tr><tr id="test-228"><td data-title="Citation"><span>2021</span> <span>Bahr TM, Shakib JH, Stipelman CH, Kawamoto K, Lauer S, Christensen RD.</span> <span>J Pediatr. 2021 Nov;238:168-173.e2.</span></td><td data-title="Sample size & Inclusion criteria">170 Infants receiving phototherapy</td><td data-title="Country of origin">USA</td><td data-title="Conclusions"><ul><li>Higher ETCOc values were associated with earlier treatment and with and longer duration of phototherapy, and ETCOc has predictive value to prevent readmission.</li><li>There is no associations between ETCOc and birth weight, gestational age, maximum total serum bilirubin (TSB) during hospitalization, positive direct Coombs test, age at maximum TSB, or length of hospital stay.</li><li>However, there is an association between ETCOc (considered as either a continuous or categorical variable) with the age of initiation of phototherapy.</li><li>ETCOc measurement will be increasingly important to both avoid the risks of phototherapy for infants who do not require it, and to ensure increased vigilance of those with high ETCOc who are at risk of bilirubin neurotoxicity.</li><li>For every 1ppm increase, phototherapy needs to start 9.1 hours early or extend 9.3 hours.</li><li>DAT is an unreliable marker of clinically relevant hemolysis. Dropping DAT from their protocol will save the hospital approximately $200,000/year.</li></ul></td></tr><tr id="test-231"><td data-title="Citation"><span>2020</span> <span>Elsaie AL, Taleb M, Nicosia A, Zangaladze A, Pease ME, Newton K, Schutzman DL.</span> <span>J Perinatol. 2020 Oct;40(10):1513- 1517.</span></td><td data-title="Sample size & Inclusion criteria">191 &lt; 35 wks, ETCOc and DAT positive</td><td data-title="Country of origin">USA</td><td data-title="Conclusions"><ul><li>Only 27.2% of 191 DAT(+) infants were hemolyzing based on ETCOc, while 29.1% of DAT (-) infants were hemolyzing based on ETCOc.</li><li>Applying the AAP criteria for initiating phototherapy, the researchers found that the management of 9.4% of the infants would have been different had ETCOc been used as an indicator of significant hemolysis as opposed to DAT(+).</li><li>13 of 18 infants would have avoided phototherapy. TSB screening results do not have a turnaround time that is rapid enough to be useful for the clinical management of HB.</li><li>Thus, the use of ETCOc should be valuable for identifying those infants who are at increased risk of BIND.</li><li>ETCOc is a more accurate determinant of hemolysis in the newborn, and its use can lead to less phototherapy</li></ul></td></tr><tr id="test-232"><td data-title="Citation"><span>2023</span> <span>Ruparel JN, Madani A, Escovedo C, Henry A, Nadar K, Rabizadeh S, Bhutani V, Berger G, Reanton G, and Mirocha J. </span><span>American Academy of Pediatrics (AAP) Presentation, Oct 2023</span></td><td data-title="Sample size & Inclusion criteria">122+600 &lt; 35 wks, TB &gt;75th percentile, 122 intervention, 600 control</td><td data-title="Country of origin">USA</td><td data-title="Conclusions"><ul><li>ETCOc enhances routine management of neonatal HB in well-baby nursery by decreasing the number of lab tests ordered and potentially reducing cost and blood testing burden.</li></ul></td></tr><tr id="test-173"><td data-title="Citation"><span>2023</span> <span>Christensen RD, Bahr TM, Wong RJ, Vreman HJ, Bhutani VK, Stevenson DK.</span> <span>J Perinatol. 2023 Jul 19.</span></td><td data-title="Sample size & Inclusion criteria">Review of studies</td><td data-title="Country of origin"></td><td data-title="Conclusions"><ul><li>The predominant cause of elevated TSB is an increase in bilirubin production primarily due to ongoing hemolysis.</li><li>The diagnosis of ABO hemolytic disease of the newborn (HDN) and optimal management can be improved by ETCOc technology.</li><li>ETCOc, in combination with TSB/TcB, can be used to identify and predict hemolytic hyperbilirubinemia requiring phototherapy or readmission in the early postnatal period (late-first week of life).</li></ul></td></tr></tbody></table></div></div></div></section></main><footer class="footer"><div class="footer__container container"><div class="footer__logo"><a class="footer__logo-link" href="index.html"><img class="footer__logo-image" src="./img/logo-footer.svg" width="174" height="39" alt="Capnia logo"></a></div><div class="footer__wrapper"><div class="footer__customer"><ul class="footer__social"><li class="footer__social-item"><a class="footer__social-link footer-link" href="privacy-statement.html">Customer Support</a></li><li class="footer__social-item"><a class="footer__social-link footer__social-link--careers footer-link" href="https://www.linkedin.com/company/capnia-inc./jobs/" target="_blank">Careers</a></li><li class="footer__social-item"><a class="footer__social-link footer__social-link--follow footer-link" href="https://www.linkedin.com/company/capnia-inc./about/" target="_blank">Follow Us</a></li><li class="footer__social-item"><a class="footer__social-link bilitool footer-link" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></li></ul></div><div class="footer__contact"><a class="footer__contact-link footer-link" href="#">Contact Us</a><address class="footer__contact-address footer-contact-item footer-contact-item--address">1101 Chess Drive Foster City, CA 94404</address><a class="footer__contact-tel footer-contact-item footer-contact-item--tel" href="tel:8664323788"><span class="footer__contact-text">Tel:</span> <span class="footer__contact-descr">(866) 432-3788</span> </a><a class="footer__contact-email footer-contact-item footer-contact-item--email" href="mailto:info@capnia.com"><span class="footer__contact-text">Email:</span> <span class="footer__contact-descr footer__contact-descr--email">info@capnia.com</span></a></div><a class="bilitool bilitool--mobile" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></div><div class="footer__info"><div class="footer__info-content"><span class="footer__info-item">CAPNIA, Inc. © 2024</span> <span class="footer__info-item">All Rights Reserved</span></div><div class="footer__info-content"><a class="footer__info-item" href="terms-of-use.html">Terms of Use</a> <a class="footer__info-item" href="privacy-statement.html">Privacy Statement</a></div></div></div></footer></div></body></html>